Your browser is no longer supported. Please, upgrade your browser.
Settings
RTTR Ritter Pharmaceuticals, Inc. daily Stock Chart
RTTR [NASD]
Ritter Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.44 Insider Own0.20% Shs Outstand15.37M Perf Week-6.03%
Market Cap8.27M Forward P/E- EPS next Y-0.83 Insider Trans100.85% Shs Float11.81M Perf Month-10.33%
Income-14.80M PEG- EPS next Q-0.13 Inst Own13.10% Short Float12.25% Perf Quarter-11.40%
Sales- P/S- EPS this Y34.40% Inst Trans-31.76% Short Ratio4.38 Perf Half Y-70.44%
Book/sh0.22 P/B2.45 EPS next Y-97.60% ROA-218.30% Target Price4.25 Perf Year-61.84%
Cash/sh0.35 P/C1.53 EPS next 5Y- ROE-399.30% 52W Range0.50 - 3.75 Perf YTD-80.15%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-85.65% Beta-
Dividend %- Quick Ratio2.10 Sales past 5Y- Gross Margin- 52W Low7.60% ATR0.04
Employees5 Current Ratio2.10 Sales Q/Q- Oper. Margin- RSI (14)44.11 Volatility6.24% 6.79%
OptionableNo Debt/Eq0.00 EPS Q/Q70.80% Profit Margin- Rel Volume0.12 Prev Close0.53
ShortableNo LT Debt/Eq0.00 EarningsAug 14 Payout- Avg Volume330.34K Price0.54
Recom2.00 SMA20-5.22% SMA50-5.64% SMA200-65.36% Volume41,239 Change1.13%
Aug-08-17Reiterated Chardan Capital Markets Buy $3.50 → $1.50
Mar-30-17Reiterated Chardan Capital Markets Buy $4.50 → $3.50
Mar-29-17Downgrade Maxim Group Buy → Hold
Jan-04-17Initiated Rodman & Renshaw Buy $7
Dec-12-16Initiated ROTH Capital Buy
Nov-07-16Reiterated Maxim Group Buy $6 → $4
Oct-25-16Reiterated Chardan Capital Markets Buy $3 → $3.30
Aug-15-16Reiterated Maxim Group Buy $7 → $6
Apr-14-16Initiated Maxim Group Buy $7
Dec-02-15Initiated Chardan Capital Markets Buy $3
Aug-22-17 07:10AM  Corporate News Blog - Ritter Pharma Announces Phase-3 Plans After End of Phase-2 Meeting with the FDA on RP-G28 for Lactose Intolerance ACCESSWIRE
Aug-21-17 08:10AM  Today's Research Reports on Stocks to Watch: Amicus Therapeutics Inc. and Ritter Pharmaceuticals Inc. ACCESSWIRE
Aug-18-17 09:30AM  Ritter Pharmaceuticals Announces Phase 3 Plans after its End of Phase 2 Meeting with FDA on RP-G28 for Lactose Intolerance Marketwired +13.21%
Aug-11-17 08:21AM  Zacks.com featured highlights: Post Holdings, Duluth Holdings, Ritter Pharmaceuticals, Koppers Holdings and Silicon Laboratories Zacks
Aug-07-17 06:18AM  Ritter Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update Marketwired
Aug-03-17 09:30AM  Ritter Pharmaceuticals Reports Further Analysis from its Phase 2b/3 Trial Results Demonstrating Significant Reductions in Lactose Intolerance Symptoms Marketwired +8.77%
May-09-17 07:26AM  Ritter Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Business Updates Marketwired
May-02-17 12:45PM  Ritter Pharmaceuticals Announces Issuance of New Patents for its Lactose Intolerance Treatment, RP-G28, and Provides an Update on its Path Forward into Phase 3 GlobeNewswire +12.19%
Apr-12-17 10:00AM  Ritter Pharmaceuticals, Inc. Announces End of Phase 2 Meeting with the FDA and Initiates Phase 3 Program Development Activities Marketwired
Mar-29-17 03:44PM  RITTER PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits -17.95%
10:46AM  Ritter Pharmaceuticals downgraded by Maxim Group
Mar-28-17 06:28PM  Ritter Pharmaceuticals Announces Lactose Intolerance Treatment, RP-G28, Demonstrated Efficacy and Clinically Meaningful Benefit in Phase 2b/3 Clinical Trial Marketwired
Mar-13-17 05:26PM  RITTER PHARMACEUTICALS INC Files SEC form 8-K, Other Events
Mar-03-17 01:04PM  RITTER PHARMACEUTICALS INC Financials
Mar-02-17 05:21PM  Penny Stocks to Watch for March 2017 (MOBL) at Investopedia +14.18%
Feb-27-17 01:51PM  RITTER PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
09:00AM  Ritter Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update Marketwired
06:16AM  RITTER PHARMACEUTICALS INC Files SEC form 10-K, Annual Report
Feb-13-17 09:00AM  Ritter Pharmaceuticals Announces Collaboration with University of British Columbia to Explore Development of Microbiome Therapeutics in Environmental Enteropathy Marketwired
Jan-30-17 09:00AM  Ritter Pharmaceuticals to Ring Today's Nasdaq Stock Market Closing Bell to Kick-off Lactose Intolerance Awareness Month Marketwired +13.53%
08:48AM  Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) to Ring The Nasdaq Stock Market Closing Bell GlobeNewswire
Jan-23-17 09:00AM  Ritter Pharmaceuticals Announces Collaboration with University of Nebraska to Explore Development of Microbiome Therapeutics in Metabolic Syndrome Marketwired
Jan-17-17 08:31AM  RITTER PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Ex
08:00AM  Ritter Pharmaceuticals Appoints William Merino, Ph.D., to its Board of Directors Marketwired
Jan-05-17 11:22AM  Penny Stocks to Watch for January 2016 Investopedia +5.42%
Jan-03-17 05:34PM  Ritter Pharmaceuticals Phase 2a Lactose Intolerance Clinical Trial Microbiome Data, Published in Proceedings of the National Academy of Sciences Marketwired +6.64%
Nov-28-16 09:00AM  Ritter Pharmaceuticals, Inc. to Present at the 9th Annual LD Micro Main Event on December 7, 2016 Accesswire
Nov-07-16 08:35AM  RITTER PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
08:30AM  Ritter Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Business Update Marketwired
06:15AM  RITTER PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
Oct-31-16 04:01PM  RITTER PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers
Oct-27-16 06:05AM  RITTER PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E -5.60%
Oct-26-16 08:00AM  Ritter Pharmaceuticals, Inc. Prices $5,000,000 Public Offering of Common Stock Marketwired
Oct-25-16 05:22PM  RITTER PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosur -18.75%
05:20PM  Ritter Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock Marketwired
Oct-19-16 01:00PM  Heres Why Traders Are Piling Into These Five Stocks at Insider Monkey +20.43%
Oct-17-16 08:30AM  Ritter Pharmaceuticals Concludes Last Patient Visit of Its Phase 2b/3 Clinical Trial of RP-G28 for the Treatment of Lactose Intolerance Marketwired +10.00%
Oct-06-16 01:28PM  Ritter Pharmaceuticals Inc (RTTR): Knoll Capital Management Reports New Position at Insider Monkey +12.36%
Oct-05-16 12:06PM  Ritter Pharmaceuticals Presents at the 4th Microbiome R&D Business Collaboration Forum Marketwired
Sep-22-16 01:10PM  5 Stocks Under $10 That Could Make You a Lot of Money +7.10%
Aug-15-16 08:30AM  Ritter Pharmaceuticals Completes Enrollment for Phase 2b/3 Trial of RP-G28 in Lactose Intolerance Marketwired +7.81%
Aug-08-16 08:30AM  Ritter Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update Marketwired
06:24AM  RITTER PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
Jul-25-16 03:17PM  Why These Five Stocks Are Trending Today at Insider Monkey +12.32%
Jun-28-16 08:30AM  Ritter Pharmaceuticals Issued Method of Use Patent for RP-G28 Marketwired
Jun-06-16 02:41PM  RITTER PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a
May-09-16 07:32AM  RITTER PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
07:00AM  Ritter Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Business Update Marketwired
06:35AM  RITTER PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
Mar-21-16 01:42PM  Ritter Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Business Update at noodls
11:24AM  Ritter Pharmaceuticals Doses First Patient in Phase 2b/3 Trial of RP-G28 in Lactose Intolerance at noodls
08:00AM  Ritter Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Business Update Marketwired
06:31AM  RITTER PHARMACEUTICALS INC Files SEC form 10-K, Annual Report
06:00AM  Ritter Pharmaceuticals Doses First Patient in Phase 2b/3 Trial of RP-G28 in Lactose Intolerance Marketwired
Mar-14-16 08:30AM  Ritter Pharmaceuticals Initiates Phase 2B/3 Clinical Trial of RP-G28 in Lactose Intolerance Marketwired
Mar-10-16 08:48AM  Ritter Pharmaceuticals to Present at the 28th Annual ROTH Conference GlobeNewswire +7.23%
Feb-16-16 08:30AM  Ritter Pharmaceuticals Issued Two New Patents Marketwired
Jan-05-16 06:11AM  RITTER PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement
Dec-21-15 06:15AM  Ritter Pharmaceuticals Enters Into a $10 Million Common Stock Purchase Agreement With Aspire Capital Fund Marketwired +18.44%
06:07AM  RITTER PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equit
Nov-25-15 01:06PM  Hedge Funds Arent Fond Of Ritter Pharmaceuticals Inc (RTTR) Anymore at Insider Monkey
Nov-17-15 08:30AM  Ritter Pharmaceuticals Provides Third Quarter 2015 Financial Results and Business Update Business Wire
Nov-10-15 03:41PM  RITTER PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
Oct-26-15 04:40PM  RITTER PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers
Oct-21-15 08:30AM  Ritter Pharmaceuticals Appoints William J. Sandborn, M.D. to Medical Advisory Board Business Wire +6.11%
Oct-06-15 08:30AM  Ritter Pharmaceuticals Appoints AnnKatrin Petersen-Jappelli, M.D., M.SC. as Chief Medical Officer Business Wire
Oct-01-15 08:30AM  Ritter Pharmaceuticals to Present at the 2015 Aegis Growth Conference Business Wire +7.32%
Sep-22-15 02:40PM  RITTER PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers
Sep-08-15 04:15PM  Ritter Pharmaceuticals to Present at the 3rd Microbiome R&D Business Collaboration Forum Business Wire
Sep-04-15 07:12AM  3 Breakout Stocks Under $10 to Trade Now at TheStreet
Aug-12-15 04:20PM  RITTER PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
Aug-05-15 09:20AM  Ritter Pharmaceuticals Retains William M. Merino as Senior Clinical and Regulatory Advisor Marketwired
Jun-29-15 04:05PM  Ritter Pharmaceuticals, Inc. Announces Closing of $20,000,000 Initial Public Offering Business Wire
Jun-24-15 12:10PM  Ritter Debuts Quietly in IPO Launch
09:53AM  Ritter Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering Business Wire
09:15AM  Story Stocks from Briefing.com Briefing.com
Ritter Pharmaceuticals, Inc., a specialty pharmaceutical company, develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b/3 clinical trial for the reduction of symptoms associated with lactose intolerance. The company's product, RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine. It is also exploring the functionality and discovering the therapeutic potential gut microbiome changes may have on treating/preventing various conditions, including gastrointestinal diseases, immuno-oncology, metabolic, and liver disease. The company was formerly known as Ritter Natural Sciences, LLC and changed its name to Ritter Pharmaceuticals, Inc. in September 2008. Ritter Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Los Angeles, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FOEHR MATTHEW WDirectorMay 18Buy0.6218,00011,15535,000May 18 03:39 PM
Step Michael DCEOMay 11Buy0.6213,0008,00750,000May 12 04:38 PM